Target intelligence / Profile preview

Porosome complex

Molecular classification
Other (supramolecular lipoprotein complex), Membrane-associated protein complex, Secretory portal
01

Overview

The **Porosome complex** is a nanoscale, cup-shaped, supramolecular lipoprotein structure located at the cell plasma membrane, universally present in secretory cells[4][7]. It serves as the principal site where secretory vesicles dock and transiently fuse with the plasma membrane to release a portion of their contents to the extracellular space—a mechanism called "fractional" or "kiss-and-run" secretion[1][2][3][5]. The porosome complex is comprised of multiple proteins, including SNAREs, cytoskeletal elements (such as actin and myosin), and various structural and regulatory proteins arranged in a highly ordered manner[2][3]. Functional abnormalities of the porosome have been implicated in diverse secretory diseases, including diabetes, neurodegenerative disorders, cystic fibrosis, immune diseases, and certain cancers[6]. Emerging therapies aim to modulate or restore porosome function, either by small-molecule/nanobody approaches or by reconstituting porosome complexes in stem cell–derived therapy for secretory insufficiencies[6]. No direct drugs currently target the porosome marketed as therapies, but it is an active area of translational research.

Other names
PorosomeSecretory portalSecretory portal complex
02

Mechanism of action

Modulation of vesicle fusion/docking; Modulation of porosome-lipid/protein interactions; Restoration or enhancement of secretory machinery (e.g., porosome reconstitution in beta cells for diabetes therapy)[6]

03

Biological functions

Regulated exocytosisVesicle docking and fusionFractional release of vesicular contentsCell secretion
04

Disease associations

DiabetesNeurodegenerative disease (e.g., Alzheimer's disease)Cystic fibrosisCancerImmune disordersOther secretory disorders
05

Safety considerations

Therapeutic manipulation of the porosome may disturb normal secretory pathways in multiple cell types, potentially resulting in wide-ranging side effects.Risks of immune rejection or dysregulation when used in cell-based transplantation or reconstitution therapies[6].
06

Interacting drugs

None directly approved or standardized; research efforts include small molecules and nanobodies targeting porosome structure/function[6].

1 more in the full profile.

07

Biomarkers

Currently no clinically established biomarkers specific for porosome complexes; research involves proteomic and lipidomic profiles[1][3].Structural proteins of the porosome (e.g., SNAREs, actin–myosin components)[3].

Beyond the preview

Go deeper on Porosome complex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Porosome complex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call